Skip to main content
padlock icon - secure page this page is secure

Current management of relapsing‐remitting multiple sclerosis

Buy Article:

$52.00 + tax (Refund Policy)

Multiple sclerosis was without effective disease‐modifying therapy for many years. The introduction of the injectable therapies (interferon and glatiramer acetate) some 20 years ago was considered a major advance. Recent years have heralded a revolution in treatment options with the introduction of intravenous natalizumab and, even more recently, three oral agents. We are currently in a period of determining the best use of these therapies to ensure prevention of disease progression while maintaining patient safety. Despite these new treatments, there are still many patients living with disability as a result of multiple sclerosis and significant attention must be given to symptomatic management.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: disease‐modifying treatment; multiple sclerosis; progressive multifocal leukoencephalopathy; relapsing‐remitting; symptom management

Document Type: Research Article

Publication date: October 1, 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more